145 related articles for article (PubMed ID: 36444394)
1. Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia.
Jensen CE; Montgomery ND; Galeotti J; Foster MC; Zeidner JF
J Cell Mol Med; 2022 Dec; 26(24):6079-6082. PubMed ID: 36444394
[No Abstract] [Full Text] [Related]
2. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
3. Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia.
Yunus NM; Johan MF; Ali Nagi Al-Jamal H; Husin A; Hussein AR; Hassan R
Asian Pac J Cancer Prev; 2015; 16(12):4869-72. PubMed ID: 26163606
[TBL] [Abstract][Full Text] [Related]
4. Frequency and prognostic impact of FLT3/ITD mutation in patients with acute myeloid leukaemia.
Govedarovic N; Marjanovic G
J BUON; 2011; 16(1):108-11. PubMed ID: 21674859
[TBL] [Abstract][Full Text] [Related]
5. FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice.
Bailey E; Li L; Duffield AS; Ma HS; Huso DL; Small D
Proc Natl Acad Sci U S A; 2013 Dec; 110(52):21113-8. PubMed ID: 24255108
[TBL] [Abstract][Full Text] [Related]
6. Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype.
Al-Arbeed IF; Wafa A; Moassass F; Al-Halabi B; Al-Achkar W; Abou-Khamis I
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3245-3251. PubMed ID: 34711001
[TBL] [Abstract][Full Text] [Related]
7. Molecular involvement and prognostic importance of fms-like tyrosine kinase 3 in acute myeloid leukemia.
Shahab S; Shamsi T; Ahmed N
Asian Pac J Cancer Prev; 2012; 13(9):4215-20. PubMed ID: 23167317
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of Fms-like tyrosine kinase 3 (FLT3) gene expression to FLT3/internal tandem duplication mutation in peripheral blood of acute myeloid leukemia.].
Xu B; Shi PC; Song XY; Tang JH; Zhou SY
Ai Zheng; 2009 Jun; 28(6):632-6. PubMed ID: 19635202
[TBL] [Abstract][Full Text] [Related]
9. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
[TBL] [Abstract][Full Text] [Related]
10. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.
Ostronoff F; Othus M; Kantarjian HM; Meshinchi S; Ravandi F; Hendrie PC; Faderl S; Becker PS; Cortes JE; Pagel JM; Petersdorf SH; Godwin JE; Willman CL; Pierce SA; List AF; Sandhu RK; Walter RB; Stirewalt DL; Appelbaum FR; Estey EH
Br J Haematol; 2013 Oct; 163(1):130-2. PubMed ID: 23829510
[No Abstract] [Full Text] [Related]
11. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.
Nazha A; Cortes J; Faderl S; Pierce S; Daver N; Kadia T; Borthakur G; Luthra R; Kantarjian H; Ravandi F
Haematologica; 2012 Aug; 97(8):1242-5. PubMed ID: 22532519
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
13. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia.
Liu SB; Qiu QC; Bao XB; Ma X; Li HZ; Liu YJ; Chen SN; Song YH; Wu DP; Xue SL
Cancer Sci; 2018 Dec; 109(12):3981-3992. PubMed ID: 30320942
[TBL] [Abstract][Full Text] [Related]
14. Comparing the area under the curve and peak height methods in the calculation of FLT3-ITD allelic ratio.
Di Ciaccio P; Kearney A; Ling S
Int J Lab Hematol; 2020 Oct; 42(5):e234-e236. PubMed ID: 32533751
[No Abstract] [Full Text] [Related]
15. Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia.
Blau O; Berenstein R; Sindram A; Blau IW
Leuk Lymphoma; 2013 Jan; 54(1):145-52. PubMed ID: 22721497
[TBL] [Abstract][Full Text] [Related]
16. FLT3 mutations in acute myeloid leukemia.
Kiyoi H; Naoe T
Methods Mol Med; 2006; 125():189-97. PubMed ID: 16502586
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML.
Li W; Zhang L; Huang L; Mi Y; Wang J
Leuk Res; 2012 Feb; 36(2):186-91. PubMed ID: 21907407
[TBL] [Abstract][Full Text] [Related]
18. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
[TBL] [Abstract][Full Text] [Related]
19. Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia.
Finnon R; Brown N; Moody J; Badie C; Olme CH; Huiskamp R; Meijne E; Sutmuller M; Rosemann M; Bouffler SD
Leukemia; 2012 Jun; 26(6):1445-6. PubMed ID: 22289922
[No Abstract] [Full Text] [Related]
20. Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22
Moloney JN; Stanicka J; Cotter TG
Leuk Res; 2017 Jan; 52():34-42. PubMed ID: 27870947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
